Autres langues MannKind Corporation

Actions

MNKD

US56400P7069

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
4,23 ^USD	+1,20 %		+1,20 %	+16,21 %

12:05	MannKind Corporation annonce que la FDA américaine a approuvé la demande de nouveau médicament de recherche (IND) pour commencer l'étude de phase 3 de la clofazimine en suspension pour inhalation dans les maladies pulmonaires à mycobactéries non tuberculeuses (NTM).	CI
26/03	MannKind Corporation nomme Steven B. Binder vice-président exécutif des projets spéciaux	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MannKind Gets FDA Clearance for Clofazimine IND Application	12:36
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease	12:05
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease	12:05
MannKind Repays Certain Debt Obligations	03/04
MannKind CFO Binder to Retire in April, Names New CFO	26/03
MannKind Announces CFO Transition	26/03
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	26/03
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects	26/03
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps	11/03
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	11/03
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8	05/03
MannKind Corporation Announces Participation at Upcoming Conferences	04/03
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M	27/02
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update	27/02
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024	20/02
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	15/02
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	15/02
MannKind Announces Up To $200 Million Royalty Purchase Agreement With Sagard Healthcare	09/01
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues MannKind Corporation

Actions

MNKD

US56400P7069

Autres langues

Filtres